{"entity":{"id":"paper-hidalgo-pancreatic-cancer-review-nejm-2010","kind":"paper","name":"Pancreatic cancer","aka":[],"tldr":"The 2010 New England Journal review that summarised what was known about pancreatic cancer at the end of the gemcitabine era, a year before FOLFIRINOX changed treatment.","summary":"Manuel Hidalgo's review in the New England Journal of Medicine, 29 April 2010, pages 1605 to 1617. Europe PMC indexes no abstract for this article, so OnCo carries no figures from it. It is used on this roadmap as the marker of where the field stood before combination chemotherapy (2011, 2013), genomic subtyping (2015, 2016), PARP inhibition for germline BRCA carriers (2019) and KRAS inhibition (2021 onward).","asOf":"2026-09-24","links":[{"label":"N Engl J Med 2010","url":"https://doi.org/10.1056/NEJMra0901557"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/20427809/"}],"tags":["pancreatic-evidence"],"related":["paper-burris-gemcitabine-pancreatic-jco-1997","paper-conroy-folfirinox-pancreatic-nejm-2011"],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2010,"doi":"10.1056/NEJMra0901557","pmid":"20427809","authors":"Hidalgo M.","paperType":"review","findings":["No abstract is indexed on Europe PMC; the review is read from the journal."],"whatItMeans":"A fixed point for readers who want to see how much, and how little, has changed since 2010.","caveats":["A review, not primary evidence; superseded on treatment by every guideline on this page."]},"route":"/key-papers/paper-hidalgo-pancreatic-cancer-review-nejm-2010/","neighbours":{"paper":[{"id":"paper-burris-gemcitabine-pancreatic-jco-1997","kind":"paper","name":"Burris 1997: gemcitabine becomes the first standard treatment for advanced pancreatic cancer","route":"/key-papers/paper-burris-gemcitabine-pancreatic-jco-1997/"},{"id":"paper-conroy-folfirinox-pancreatic-nejm-2011","kind":"paper","name":"Conroy 2011: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (PRODIGE 4/ACCORD 11)","route":"/key-papers/paper-conroy-folfirinox-pancreatic-nejm-2011/"}],"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}],"roadmap":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"}]}}